« Return to News | CROs/Service Providers

Health Decisions Adds Klixar to Network

Thursday, December 3, 2009 08:20 AM

Durham, N.C.-based Health Decisions, a full-service CRO specializing in high-efficiency adaptive solutions, announced that Argentina-based CRO Klixar has joined its Agile Clinical Network—a newly launched community of research partners formed to eliminate the information gaps and prolonged timelines of complex global studies.

As a network member, Klixar will share key resources, best practices and partnership opportunities with Health Decisions and other CROs that have embraced Agile Clinical Development—a methodology that combines adaptive design with adaptive operations to cut trial timelines and increase transparency—as the key to efficient multinational trials.

 “We welcome the opportunity to partner with a leading U.S.-based CRO to ensure the highest quality deliverables for our sponsors,” said Enrique Gaubeca, managing director at Klixar.

“Our alliance with Health Decisions will enable us to broaden our customer base while providing unparalleled efficiency and transparency to pharmaceutical companies in Latin America.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.